Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Aura Biosciences, Inc. (AURA)
Company Research
Source: GlobeNewswire
Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026 BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2025, and provided recent business highlights. “In the third quarter, we remained focused on clinical execution in both our global Phase 3 CoMpass trial in early choroidal melanoma and our Phase 1b/2 trial in NMIBC,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura Biosciences. “Enrollment has taken longer than we expected in early choroidal me
Show less
Read more
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
News
- Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Aura Biosciences (NASDAQ:AURA) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
- Aura Biosciences to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Aura Biosciences: Bringing Not-Quite-Viruses Closer To Fruition In Cancer [Seeking Alpha]Seeking Alpha
- Aura Biosciences GAAP EPS of -$0.40 beats by $0.07 [Seeking Alpha]Seeking Alpha
AURA
Earnings
- 11/13/25 - Beat
AURA
Sec Filings
- 11/17/25 - Form 144
- 11/17/25 - Form 4
- 11/13/25 - Form 10-Q
- AURA's page on the SEC website